Publications - Corcept Therapeutics

PUBLICATIONS

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.

A mixed glucocorticoid/mineralocorticoid selective modulator with dominant antagonism in the male rat brain.

Atucha et al. • 2015 • Endocrinology. 2015;156(11):4105-4114.

Identification of the clinical candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): a selective Glucocorticoid Receptor (GR) antagonist.

Hunt et al. • 2017 • J Med Chem. 2017;60(8):3405-3421.

1H-pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoidreceptor antagonists with high functional activity.

Clark et al. • 2008 • Bioorg Med Chem Lett. 2008;18(4):1312-7.

Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study.

Hunt et al. • 2017 • Clin Pharmacol Drug Dev. 2017 Oct 2. doi: 10.1002/cpdd.389.

FKBP5 mRNA expression is a biomarker for GR antagonism.

Bali et al. • 2016 • J Clin Endocrinol Metab. 2016;101(11):4305-4312.

Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth.

Kach et al. • 2017 • Mol Cancer Ther. 2017;16(8):1680-1692.

Selective glucocorticoid receptor antagonist CORT125281 activates brown adipose tissue and alters lipid distribution in male mice.

Kroon et al. • 2017 • Endocrinology. 2017 Sep 18. doi:10.1210/en.2017-00512.

A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.

Mammi et al. • 2016 • Int J Obes (Lond). 2016;40(6):964-72.

Identification of a selective glucocorticoid receptor modulator that prevents both diet-induced obesity and inflammation.

van den Heuvel et al. • 2016 • Br J Pharmacol. 2016;173(11):1793-804.

Glucocorticoid antagonism limits adiposity rebound and glucose intolerance in young male rats following the cessation of daily exercise and caloric restriction.

Teich et al. • 2016 • Am J Physiol Endocrinol Metab. 2016;311(1):E56-68.